Complete financial analysis of NeoGenomics, Inc. (NEO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of NeoGenomics, Inc., a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
- Schibsted ASA (SBBTF) Income Statement Analysis – Financial Results
- Hat Trick Beverage, Inc. (HKBV) Income Statement Analysis – Financial Results
- J.S.B.Co.,Ltd. (3480.T) Income Statement Analysis – Financial Results
- Octavius Plantations Limited (OCTAVIUSPL.BO) Income Statement Analysis – Financial Results
- Deutsche Wohnen SE (DWHHF) Income Statement Analysis – Financial Results
NeoGenomics, Inc. (NEO)
About NeoGenomics, Inc.
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates through, Clinical Services and Pharma Services segments. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers. It provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. The company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization, as well as acts as a reference laboratory supplying anatomic pathology testing services. It has a strategic alliance agreement and laboratory services agreement with Inivata Limited. The company was founded in 2001 and is headquartered in Fort Myers, Florida.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 591.64M | 509.73M | 484.33M | 444.45M | 408.83M | 276.74M | 258.61M | 244.08M | 99.80M | 87.07M | 66.47M | 59.87M | 43.48M | 34.37M | 29.47M | 20.02M | 11.50M | 6.48M | 1.89M | 558.07K | 369.97K | 93.49K | 1.00K | 252.40K |
| Cost of Revenue | 347.04M | 321.83M | 297.27M | 258.56M | 211.99M | 149.48M | 138.30M | 133.70M | 56.05M | 46.36M | 34.73M | 33.03M | 24.06M | 18.59M | 14.25M | 9.35M | 5.52M | 2.76M | 1.19M | 576.87K | 481.59K | 189.96K | 0.00 | 74.29K |
| Gross Profit | 244.60M | 187.90M | 187.06M | 185.89M | 196.84M | 127.27M | 120.32M | 110.38M | 43.76M | 40.71M | 31.74M | 26.84M | 19.43M | 15.78M | 15.21M | 10.66M | 5.98M | 3.72M | 696.92K | -18.79K | -111.62K | -96.47K | 1.00K | 178.11K |
| Gross Profit Ratio | 41.34% | 36.86% | 38.62% | 41.83% | 48.15% | 45.99% | 46.52% | 45.22% | 43.84% | 46.76% | 47.75% | 44.83% | 44.68% | 45.92% | 51.63% | 53.27% | 52.00% | 57.39% | 36.97% | -3.37% | -30.17% | -103.18% | 100.00% | 70.57% |
| Research & Development | 27.31M | 30.33M | 21.87M | 8.23M | 8.49M | 3.00M | 3.64M | 4.65M | 4.20M | 2.69M | 2.44M | 2.28M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 46.41K | 0.00 | 0.00 |
| General & Administrative | 243.10M | 243.36M | 221.35M | 143.79M | 127.99M | 84.82M | 88.76M | 75.78M | 33.63M | 23.81M | 17.40M | 15.84M | 12.87M | 11.27M | 10.06M | 0.00 | 0.00 | 3.58M | 1.50M | 710.77K | 382.71K | 440.79K | 0.00 | 0.00 |
| Selling & Marketing | 70.84M | 67.32M | 62.59M | 47.86M | 47.35M | 29.40M | 24.54M | 23.91M | 11.56M | 12.00M | 8.73M | 7.50M | 6.96M | 7.48M | 6.89M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 313.04M | 310.68M | 283.94M | 191.66M | 175.34M | 114.22M | 113.30M | 99.69M | 45.19M | 35.81M | 26.12M | 23.34M | 19.84M | 18.75M | 16.94M | 11.55M | 9.12M | 3.58M | 1.50M | 710.77K | 382.71K | 440.79K | 8.08M | 1.12M |
| Other Expenses | 11.99M | -213.00K | -499.00K | 11.86M | -4.63M | 14.00K | -1.32M | 3.46M | 2.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 26.40K |
| Operating Expenses | 352.34M | 341.00M | 305.81M | 199.89M | 183.83M | 117.23M | 116.93M | 104.34M | 49.39M | 38.50M | 28.56M | 25.63M | 19.84M | 18.75M | 16.94M | 11.55M | 9.12M | 3.58M | 1.50M | 710.77K | 382.71K | 487.21K | 8.08M | 1.15M |
| Cost & Expenses | 699.38M | 662.84M | 603.08M | 458.44M | 395.82M | 266.70M | 255.23M | 238.05M | 105.44M | 84.85M | 63.29M | 58.66M | 43.89M | 37.33M | 31.20M | 20.90M | 14.65M | 6.34M | 2.69M | 1.29M | 864.30K | 677.16K | 8.08M | 1.22M |
| Interest Income | 16.90M | 6.08M | 3.14M | 3.06M | 3.71M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 6.91M | 1.51M | 5.08M | 7.02M | 3.71M | 6.23M | 5.54M | 10.00M | 854.00K | 929.00K | 989.00K | 1.15M | 768.00K | 710.00K | 532.39K | 308.52K | 0.00 | 325.63K | 196.80K | 0.00 | 41.43K | 207.31K | 0.00 | 0.00 |
| Depreciation & Amortization | 72.58M | 79.21M | 62.07M | 41.89M | 35.91M | 21.73M | 22.59M | 23.21M | 7.14M | 5.64M | 4.41M | 3.82M | 2.09M | 1.78M | 1.18M | 740.56K | 506.36K | 306.59K | 181.07K | 104.26K | 48.04K | -207.31K | 245.67K | 26.40K |
| EBITDA | -17.61M | -78.63M | 52.08M | 34.85M | 43.26M | 31.79M | 26.55M | 29.25M | 3.51M | 7.86M | 7.59M | 5.03M | 1.68M | -812.00K | -526.31K | -143.43K | -2.63M | 446.58K | -619.30K | -625.30K | -446.30K | -583.67K | -7.83M | -944.53K |
| EBITDA Ratio | -2.98% | -16.46% | 8.95% | 7.56% | 9.45% | 11.49% | 9.53% | 11.98% | 3.51% | 2.55% | 4.78% | 8.40% | 3.85% | -4.52% | -1.90% | -0.77% | -23.11% | 6.03% | -32.85% | -112.05% | -120.63% | -624.31% | -783,229.50% | -374.47% |
| Operating Income | -107.74M | -153.11M | -9.99M | -2.13M | 8.38M | 10.04M | 3.38M | 2.57M | -5.64M | 2.22M | 3.17M | 1.21M | -409.00K | -2.96M | -1.73M | -883.99K | -3.14M | 139.99K | -800.36K | -729.56K | -494.33K | -583.67K | -8.08M | -970.93K |
| Operating Income Ratio | -18.21% | -30.04% | -2.06% | -0.48% | 2.05% | 3.63% | 1.31% | 1.05% | -5.65% | 2.55% | 4.78% | 2.02% | -0.94% | -8.62% | -5.86% | -4.42% | -27.30% | 2.16% | -42.45% | -130.73% | -133.61% | -624.31% | -807,796.60% | -384.67% |
| Total Other Income/Expenses | 10.64M | -1.72M | 103.68M | -64.00K | -9.36M | -6.22M | -5.55M | -10.00M | 1.15M | -929.00K | -989.00K | -1.15M | -768.00K | -340.00K | -515.30K | -498.60K | -239.20K | -139.99K | -196.80K | -89.42K | 0.00 | 0.00 | 0.00 | 646.00 |
| Income Before Tax | -97.10M | -159.34M | -15.08M | -14.06M | 3.65M | 3.82M | -3.48M | -7.42M | -4.49M | 1.29M | 2.19M | 65.00K | -2.70K | -2.59M | -1.71M | -1.07M | -3.12M | 139.99K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -970.28K |
| Income Before Tax Ratio | -16.41% | -31.26% | -3.11% | -3.16% | 0.89% | 1.38% | -1.35% | -3.04% | -4.50% | 1.48% | 3.29% | 0.11% | -0.01% | -7.54% | -5.80% | -5.37% | -27.09% | 2.16% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -384.42% |
| Income Tax Expense | -9.13M | -15.09M | -6.73M | -18.23M | -4.36M | 1.18M | -2.64M | -1.70M | -1.95M | 157.00K | 152.00K | 1.15M | 768.00K | -740.00K | -34.18K | 180.15K | 214.94K | -111.94K | 196.80K | 89.42K | 41.43K | 214.16K | 0.00 | -1.29K |
| Net Income | -87.97M | -144.25M | -8.35M | 4.17M | 8.01M | 2.64M | -846.00K | -5.72M | -2.54M | 1.13M | 2.03M | 65.00K | -1.18M | -3.30M | -2.24M | -1.38M | -3.38M | -129.66K | -997.16K | -818.99K | -535.76K | -590.52K | -8.08M | -970.28K |
| Net Income Ratio | -14.87% | -28.30% | -1.72% | 0.94% | 1.96% | 0.95% | -0.33% | -2.34% | -2.54% | 1.30% | 3.06% | 0.11% | -2.71% | -9.61% | -7.61% | -6.91% | -29.38% | -2.00% | -52.89% | -146.75% | -144.81% | -631.64% | -807,796.60% | -384.42% |
| EPS | -0.70 | -1.16 | -0.07 | 0.04 | 0.08 | 0.03 | -0.01 | -0.07 | -0.04 | 0.02 | 0.04 | 0.00 | -0.03 | -0.09 | -0.06 | -0.04 | -0.11 | -0.01 | -0.04 | -0.04 | -0.04 | -0.14 | -2.14 | -1.24 |
| EPS Diluted | -0.70 | -1.16 | -0.07 | 0.04 | 0.08 | 0.03 | -0.01 | -0.07 | -0.04 | 0.02 | 0.04 | 0.00 | -0.03 | -0.09 | -0.06 | -0.04 | -0.11 | -0.01 | -0.04 | -0.04 | -0.04 | -0.14 | -2.14 | -1.24 |
| Weighted Avg Shares Out | 125.50M | 124.22M | 119.96M | 108.58M | 100.47M | 91.57M | 78.16M | 77.04M | 60.53M | 53.48M | 48.26M | 45.03M | 42.76M | 37.33M | 34.64M | 31.51M | 29.76M | 26.17M | 22.26M | 19.90M | 14.39M | 4.21M | 3.77M | 781.98K |
| Weighted Avg Shares Out (Dil) | 125.50M | 124.22M | 119.96M | 111.79M | 103.62M | 91.57M | 79.43M | 77.54M | 60.53M | 56.02M | 52.78M | 48.72M | 42.76M | 37.33M | 34.64M | 31.51M | 29.76M | 26.17M | 22.26M | 19.90M | 14.39M | 4.21M | 3.77M | 781.98K |
Here's What Key Metrics Tell Us About NeoGenomics (NEO) Q1 Earnings
NeoGenomics (NEO) Reports Q1 Loss, Tops Revenue Estimates
NeoGenomics Reports First Quarter 2024 Results
NeoGenomics (NEO) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
NeoGenomics Announces Senior Leadership Promotions
NeoGenomics to Report First Quarter 2024 Financial Results on April 30, 2024
NeoGenomics Showcases Commitment to Transforming Cancer Patient Care at AACR 2024 Annual Meeting
All You Need to Know About NeoGenomics (NEO) Rating Upgrade to Buy
Does NeoGenomics (NEO) Have the Potential to Rally 43.34% as Wall Street Analysts Expect?
NeoGenomics Releases Inaugural Environmental, Social, and Governance (ESG) Report
Source: https://incomestatements.info
Category: Stock Reports